Skip to content
Triangle logo TriangleGet started
← Full study record

NCT04644315 · BASELINE

Baseline characteristics

A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors · Source last updated 2023-08-07

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms
  1. counts
    1. group Id
      BG000
      value
      1
    units
    Participants
groups
  1. description
    Participants with locally advanced or metastatic ALK-positive tumors were to receive alectinib twice daily (BID) until disease progression, unacceptable toxicity, death, or withdrawal from the study for any reason.
    id
    BG000
    title
    ALK-positive Solid Tumors
measures
  1. classes
    1. denoms
      1. counts
        1. group Id
          BG000
          value
          0
        units
        Participants
    dispersion Type
    STANDARD_DEVIATION
    param Type
    MEAN
    population Description
    The risk of participant re-identification is unacceptable for a population of n=1 and this value will therefore not be provided.
    title
    Age, Continuous
    unit Of Measure
    Years
  2. classes
    1. denoms
      1. counts
        1. group Id
          BG000
          value
          0
        units
        Participants
    param Type
    COUNT_OF_PARTICIPANTS
    population Description
    The risk of participant re-identification is unacceptable for a population of n=1 and this value will therefore not be provided.
    title
    Sex/Gender, Customized
    unit Of Measure
    Participants
  3. classes
    1. denoms
      1. counts
        1. group Id
          BG000
          value
          0
        units
        Participants
    param Type
    COUNT_OF_PARTICIPANTS
    population Description
    The risk of participant re-identification is unacceptable for a population of n=1 and this value will therefore not be provided.
    title
    Race/Ethnicity, Customized
    unit Of Measure
    Participants
Complete source fields
denoms
  1. counts
    1. group Id
      BG000
      value
      1
    units
    Participants
groups
  1. description
    Participants with locally advanced or metastatic ALK-positive tumors were to receive alectinib twice daily (BID) until disease progression, unacceptable toxicity, death, or withdrawal from the study for any reason.
    id
    BG000
    title
    ALK-positive Solid Tumors
measures
  1. classes
    1. denoms
      1. counts
        1. group Id
          BG000
          value
          0
        units
        Participants
    dispersion Type
    STANDARD_DEVIATION
    param Type
    MEAN
    population Description
    The risk of participant re-identification is unacceptable for a population of n=1 and this value will therefore not be provided.
    title
    Age, Continuous
    unit Of Measure
    Years
  2. classes
    1. denoms
      1. counts
        1. group Id
          BG000
          value
          0
        units
        Participants
    param Type
    COUNT_OF_PARTICIPANTS
    population Description
    The risk of participant re-identification is unacceptable for a population of n=1 and this value will therefore not be provided.
    title
    Sex/Gender, Customized
    unit Of Measure
    Participants
  3. classes
    1. denoms
      1. counts
        1. group Id
          BG000
          value
          0
        units
        Participants
    param Type
    COUNT_OF_PARTICIPANTS
    population Description
    The risk of participant re-identification is unacceptable for a population of n=1 and this value will therefore not be provided.
    title
    Race/Ethnicity, Customized
    unit Of Measure
    Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice